
Cofactor Genomics
Cofactor Genomics is a YC Summer 2015 (S15) company. Based in St. Louis, MO, USA. Team of 13.
About Cofactor Genomics
Summary
Cofactor Genomics builds predictive diagnostic tools that help oncologists determine which cancer patients will respond to immunotherapy before treatment begins. Its OncoPrism assay uses RNA-based, multidimensional biomarker modeling to replace single-analyte diagnostics that give clinicians an incomplete picture of tumor response. The technology is being evaluated across 11 solid tumor cancers through the national PREDAPT clinical trial, with the goal of covering half of all cancers diagnosed in the US.
Go-to-market
Cofactor works with medical oncologists, pathologists, and healthcare systems, bringing them in as clinical trial partners through the PREDAPT trial before broader commercial deployment.
From the Y Combinator listing
Cofactor closes the precision medicine gap with predictive diagnostics
Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
Facts
- Healthcare / Healthcare -> Diagnostics
- St. Louis, MO, USA
- 13
- Active
- Growth
Founders (2)
- Jarret Glasscock
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works